IHEEZO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Iheezo, and what generic alternatives are available?
Iheezo is a drug marketed by Harrow Eye and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-two patent family members in twenty-two countries.
The generic ingredient in IHEEZO is chloroprocaine hydrochloride. There are four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the chloroprocaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Iheezo
A generic version of IHEEZO was approved as chloroprocaine hydrochloride by HIKMA on September 9th, 1998.
Summary for IHEEZO
| International Patents: | 22 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 58 |
| Patent Applications: | 815 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for IHEEZO |
| What excipients (inactive ingredients) are in IHEEZO? | IHEEZO excipients list |
| DailyMed Link: | IHEEZO at DailyMed |
Pharmacology for IHEEZO
| Drug Class | Ester Local Anesthetic |
| Physiological Effect | Local Anesthesia |
Anatomical Therapeutic Chemical (ATC) Classes for IHEEZO
US Patents and Regulatory Information for IHEEZO
IHEEZO is protected by one US patents and one FDA Regulatory Exclusivity.
Patents protecting IHEEZO
Topical formulations of chloroprocaine and methods of using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF INDUCING OCULAR ANESTHESIA
FDA Regulatory Exclusivity protecting IHEEZO
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | IHEEZO | chloroprocaine hydrochloride | GEL;OPHTHALMIC | 216227-001 | Sep 27, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Harrow Eye | IHEEZO | chloroprocaine hydrochloride | GEL;OPHTHALMIC | 216227-001 | Sep 27, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for IHEEZO
See the table below for patents covering IHEEZO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Eurasian Patent Organization | 202090735 | СОСТАВЫ ХЛОРПРОКАИНА ДЛЯ МЕСТНОГО ПРИМЕНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | ⤷ Try a Trial |
| Philippines | 12020550029 | TOPICAL FORMULATIONS OF CHLOROPROCAINE | ⤷ Try a Trial |
| China | 111163756 | 氯普鲁卡因的局部制剂 (TOPICAL FORMULATIONS OF CHLOROPROCAINE) | ⤷ Try a Trial |
| Morocco | 50241 | FORMULATIONS TOPIQUES DE CHLOROPROCAÏNE | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2019053657 | ⤷ Try a Trial | |
| Colombia | 2020002985 | Formulaciones tópicas de cloroprocaína | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
